Navigation Links
ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation
Date:3/14/2010

ATLANTA, Georgia, March 14, 2010 /PRNewswire/ -- Cardiovascular risk can be reduced by an additional 31 percent in type 2 diabetes patients with atherogenic dyslipidemia, the common combination of elevated triglycerides (TG, 204 mg/dL or 2.3 mmol/L or higher) and low levels of high-density lipoprotein cholesterol (HDL-C, 34 mg/dL or 0.88 mmol/L or lower). This is achieved by adding fenofibrate to simvastatin. Only 20 of these patients need to be treated for 5 years to prevent one cardiovascular event.

To view the Multimedia News Release, please click: http://multivu.prnewswire.com/mnr/r3i/42622/

In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid trial, published on-line in the New England Journal of Medicine,(1) the group with atherogenic dyslipidemia had 70 percent more cardiovascular events (cardiovascular death, heart attacks and strokes) than patients without. In fact, the risk associated with atherogenic dyslipidemia was comparable to that in people with previous cardiovascular disease (17.3 percent versus 18.1 percent).


'/>"/>
SOURCE Residual Risk Reduction initiative (R3i)
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
2. Symmetry Medical to Present at Canaccord Adams Small-Cap Orthopedics Conference
3. Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
4. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
5. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
6. Osteotech to Present at the Canaccord Adams Small-Cap Orthopedics Conference in San Francisco
7. C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study
8. As Billions in Blockbuster Drug Revenue Goes Off Patent, Life Sciences Companies are Challenged to Fundamentally Change Future R&D Strategies, According to New Deloitte Report
9. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
10. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
11. Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22 de enero de 2015  El Dr. Paul ... llamada a nominaciones para 2015. Este prestigioso premio reconoce ... tiene el potencial para hacer, contribuciones destacadas para la ... hasta el 15 de marzo de 2015 a través ...
(Date:1/22/2015)... 22, 2015   GenoSpace , a precision medicine software company ... the broad use of genomic, imaging and other biomedical data ... Michelle Munson , CEO of Aspera, an IBM Company, ... - http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... BOTHELL, Wash. , Dec. 24, 2014   BioLife Solutions ... manufacturer and marketer of proprietary clinical grade hypothermic storage ... thermal shipping products for cells and tissues  ("BioLife" or ... Annual Meeting of Stockholders on May 4, 2015 (the "Annual ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... Ltd. (Bovespa:,AGEN11), one of the largest provider of integrated ... to its,shareholders and investors that, on April 10, 2008, ... acquisition of 264,000 m3 of,biodiesel, for delivery between July ... was to ensure supply of the necessary volumes for ...
... Inc.,(Amex: SGN ) has confirmed that it has ... Executive Officer, Dr. Lowell T. Harmison, has,scheduled a webcast ... Dr. Harmison stated: "Now that Signalife has closed filing ... shipping,product, I am pleased to provide direction on new ...
... SIAL ), will hold its quarterly conference ... 23, 2008, at 11:00 a.m. Eastern Time,(10 a.m. ... by Thomson/CCBN and can be accessed at,Sigma- Aldrich,s ... webcast is also being distributed through the Thomson ...
Cached Biology Technology:Signalife Announces Webcast 2Signalife Announces Webcast 3Sigma-Aldrich Corporation 1st Quarter 2008 Earnings Conference Call 2
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric ... recent success of the Wocket™ smart wallet at CES 2015 in ... named as one of the "11 Hot Products at CES" in a ... CES So Far" by Newseveryday.com and "The top 10 gadgets from CES ...
(Date:1/22/2015)... 21, 2015  Analyst Report Issued by Small Cap IR. In ... that planet-wide, transactions at merchants on the leading payment cards ... of credit, debit, and prepaid cards reached 6.54 billion.  Eight ... fraudulent card usage in 2012, and credit and debit card ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... of the "Global Wearable Technologies Market and ... Overview, Trends and Forecast 2014-2020" report to ... are smart devices that can be worn on ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... definitely something to be said for first impressions. New ... can take just 20 seconds to detect whether a ... compassionate. The findings reinforce that healthy humans are ... in a tough situation. They also pave the way ...
... 90 percent of cancer deaths are caused by secondary tumors, ... To become mobile and break free from the original ... environment. Many cells have been implicated in this process, including ... collaborator in metastasis is platelets, the blood cells whose normal ...
... rare and neglected diseases that include potential treatments for ... that affects the central nervous system of newborns, a ... a rare lung disease. The six new projects are ... Rare and Neglected Diseases (TRND) program. "These projects ...
Cached Biology News:Is a stranger trustworthy? You'll know in 20 seconds 2MIT: Uncovering a key player in metastasis 2MIT: Uncovering a key player in metastasis 3NIH TRND program announces next round of drug development projects 2NIH TRND program announces next round of drug development projects 3NIH TRND program announces next round of drug development projects 4NIH TRND program announces next round of drug development projects 5
Human RXR beta/NR2B2 MAb (Clone H7341) Keywords: RXRbeta, RXRbeta, Retinoid X Receptor beta...
Human SOST Affinity Purified Polyclonal Ab...
BOND ELUT MATRIX-C18, 25 mg ...
Prepared from plasminogen by activation with immobilized human uPA...
Biology Products: